Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter, Prospective Study of Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT06282874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter, Prospective Study of Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Phase 4
Overall status
Active, not recruiting
Start date
August 1, 2024
Completion date
March 1, 2027
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, carcinoma, non-small-cell lung, leptomeningeal metastasis